Eosinophilic Asthma

Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving dupilumab for 24 weeks.

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.

Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results published in European Respiratory Journal.

BOSTON — ICU patients with an eosinophilic asthma phenotype had longer ICU and hospital stays compared with patients without an eosinophilic asthma type, according to an abstract presented at the CHEST Annual Meeting.

Patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma showed significant improvements in asthma control and acute vasculitis symptoms after 1 year of benralizumab, according to real-world study results.

Mepolizumab and benralizumab were associated with prolonged reductions in oral corticosteroid use among real-world patients with severe eosinophilic asthma, according to data in The Journal of Allergy and Clinical Immunology: In Practice.

SAN ANTONIO — Patients with severe eosinophilic asthma experienced improvements in their symptoms within a week after taking benralizumab, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN ANTONIO — Seventy percent of patients with severe eosinophilic asthma on mepolizumab for 5 to 6 years had no exacerbations for 1 year, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

A group of biomarkers proposed in previous research insufficiently diagnosed eosinophilic phenotypes among patients with asthma, according to a study published in Clinical and Translational Allergy.

Phenotype-directed mepolizumab therapy reduced the number of asthma exacerbations among children and adolescents with exacerbation-prone eosinophilic asthma who live in disadvantaged urban neighborhoods, researchers reported in The Lancet.